Evidence map›Paper›PMID 40661453›Full record

ArticlebioRxiv : the preprint server for biology2025

Rational Design of Immunogenic Nanoparticles as a Platform for Enhanced Ovarian Cancer Immunotherapy in Mice.

Lien Tang, Ben Marwedel, Caleb Dang, Marian Olewine, Melanie Jun, Paulina Naydenkov, Lorél Y Medina, Veronica Gayoso, Ngoc Doan, Shamus L O'Leary and 7 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Lien TangChemical and Biological Engineering, University of New Mexico, Albuquerque, NM, USA.
Ben MarwedelDepartment of Internal Medicine, University of New Mexico, Albuquerque, NM, USA.
Caleb DangChemical and Biological Engineering, University of New Mexico, Albuquerque, NM, USA.
Marian OlewineChemical and Biological Engineering, University of New Mexico, Albuquerque, NM, USA.
Melanie JunDepartment of Internal Medicine, University of New Mexico, Albuquerque, NM, USA.
Paulina NaydenkovChemical and Biological Engineering, University of New Mexico, Albuquerque, NM, USA.
Lorél Y MedinaDepartment of Internal Medicine, University of New Mexico, Albuquerque, NM, USA.
Veronica GayosoChemical and Biological Engineering, University of New Mexico, Albuquerque, NM, USA.
Ngoc DoanChemical and Biological Engineering, University of New Mexico, Albuquerque, NM, USA.
Shamus L O'LearyCenter for Integrated Nanotechnologies, Los Alamos National Laboratory, Los Alamos, USA.
Carmine SchiavoneMathematics in Medicine Program, Department of Medicine, Houston Methodist Research Institute, Houston, TX, 77030, USA.
Joseph CaveMathematics in Medicine Program, Department of Medicine, Houston Methodist Research Institute, Houston, TX, 77030, USA.
Tamara HowardDepartment of Cell Biology & Physiology, UNM School of Medicine, Albuquerque, NM, USA.
John D WattCenter for Integrated Nanotechnologies, Los Alamos National Laboratory, Los Alamos, USA.
Prashant DograMathematics in Medicine Program, Department of Medicine, Houston Methodist Research Institute, Houston, TX, 77030, USA.
Rita E SerdaDepartment of Internal Medicine, University of New Mexico, Albuquerque, NM, USA.
Achraf NoureddineChemical and Biological Engineering, University of New Mexico, Albuquerque, NM, USA.

Funding

WOMEN'S CANCERS RESEARCH PROGRAMP30CA118100 · NCI · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI Yolanda Sanchez · 2005 to 2026
$57.1M
Unfolded Protein Response and Autophagy in T Helper Cell Effector FunctionP20GM121176 · NIGMS · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI Samuel Joseph Endicott · 2017 to 2026
$24.9M
University of New Mexico Center for Metals in Biology and Medicine - equipment supplementP20GM130422 · NIGMS · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI Sebastian Medina · 2020 to 2026
$20.4M
Artificial intelligence-integrated mechanistic modeling for rational design of nanoparticles to improve organ targeting and safetyR01EB035545 · NIBIB · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Prashant Dogra, Achraf Noureddine · 2024 to 2026
$1.3M
NCI NIH HHS P30 CA118100NIBIB NIH HHS R01 EB035545NIGMS NIH HHS P20 GM121176NIGMS NIH HHS P20 GM130422
6 · The paper itself

Abstract

Ovarian cancer immunotherapy remains a challenge based on the "cold" tumor microenvironment. Herein we present a rational design to create immunogenic nanoparticles as a multi-agent platform that promotes immune response in a mouse model of ovarian cancer. The hybrid lipid-silica nanosystem is capable of co-loading four types of cargo molecules including a model antigen, nucleic acid-based adjuvant Cytosine-p-linked to Guanine (CpG, TLR3/9 agonist), lipid-based adjuvant (MPLA, TLR4 agonist) integrated into the lipid coat, and optionally a small molecule drug, such as the chemotherapeutic agent oxaliplatin, a well-established treatment for ovarian cancer. The optimization of the nanoplatform in terms of lipid composition, functionalized silica dendritic core formation, and final charge, as well as their compatibility with the complex loading profile highlights an opportunity for enhanced survival of mice with advanced ovarian cancer compared to monotherapy. Furthermore, intraperitoneal administration led to preferential accumulation within tumor-burdened tissues with selective accumulation in myeloid cells. High myeloid cell cytotoxicity negated the benefits of oxaliplatin. The inclusion of CpG in the nanoparticle formulation enhanced the survival of mice with ovarian cancer. To interpret these outcomes and guide future design, we also developed a mathematical model of nanoparticle-driven immune activation, which quantified treatment efficacy and identified key parameters governing tumor response. The presented hybrid nanoparticle is tunable, enabling delivery of alternative molecules therefore, thereby highlighting a promising platform for the treatment of peritoneal cancers.

Identifiers

PMID40661453
PMCPMC12258945

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.